Formycon and Fresenius Kabi Launch Otulfi™ in Canada

Formycon AG and Fresenius Kabi have announced the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar, in Canada. This product is available in both subcutaneous and intravenous formulations. The launch aims to broaden treatment options for patients suffering from chronic autoimmune diseases like Crohn's disease and ulcerative colitis.

Otulfi™ has been granted a Notice of Compliance by Health Canada and offers a cost-effective alternative to existing treatments. To assist patients, Fresenius Kabi provides the KabiCare® support program, which includes services such as injection training and reimbursement assistance.

Ustekinumab targets cytokines relating to inflammatory and immune responses, approved previously by the FDA and EMA. The product is available as prefilled syringes and vials for different methods of administration.